CagriSema vs Pramlintide
A side-by-side research comparison of CagriSema and Pramlintide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CagriSema | Pramlintide |
|---|---|---|
| Full name | CagriSema (Cagrilintide + Semaglutide) | Pramlintide (Symlin) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | FDA Approved |
| Mechanism | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. | Mimics amylin by activating amylin receptors, which slows gastric emptying, suppresses inappropriate glucagon secretion after meals, and increases satiety - complementing insulin's effects. |
| Molecular weight | Combination product | 3949.4 Da |
| Half-life | 7 days (both components) | ~48 minutes |
| Bioavailability | High (SubQ) | Subcutaneous injection |
| Typical dose | Cagrilintide 2.4mg + Semaglutide 2.4mg | 15-120 mcg before meals |
| Frequency | Once weekly | Before major meals |
| Route | Subcutaneous | Subcutaneous injection |
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Pramlintide reported benefits
- Appetite suppression and satiety
- Slows gastric emptying
- Improves post-meal glucose control
- Modest weight loss
Related comparisons
Research and educational reference only. Not medical advice.